{"changeSha256":"5b31218a1ce38891de21106a239211c15186ca9b52547de94ae8ce67f962ac24","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products","before":"U.S. label record","field":"Status"},{"after":"A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.","before":"A GnRH agonist. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.","before":"The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"Leuprolide acetate, Lupron, Eligard, Vobrig","before":"Leuprolide acetate","field":"Related names"},{"after":"dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183","before":"dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]","before":"U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]","field":"Named organizations"},{"after":"name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, journal-pmid-32469183","before":"name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/leuprolide/versions/3/","version":3},"id":"profile:leuprolide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, Drugs@FDA approval records for leuprolide products, FDA’s August 26, 2026 approval of Vobrig for central precocious puberty, and the HERO trial. DailyMed no longer serves the cited label version, so we checked it against the current rendering of the same label set.","peptideSlugs":["leuprolide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/leuprolide/v2.json","sha256":"94562f9b2c794a8402bf54f4283f72d021a97048f6a0fe0b180a778702973903"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/leuprolide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"Leuprolide acetate kit · SPL version 10 · published 2026-07-06","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=4838c674-044e-46b2-81e7-c691b99d8fa5&version=10","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda019010-1985-04-09-d97355079c93","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019010%22&limit=1","verifiedAt":"2026-08-14"},{"id":"fda-vobrig-approval-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213225Orig1s000ltr.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"leuprolide","type":"profile"}}
